Andere Sprachen Enliven Therapeutics, Inc.

Aktien

A3DGS0

US29337E1029

ELVN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 10.05.2024			% 5 Tage	% 1. Jan.
23,43 ^USD	-1,97 %		+3,44 %	+69,29 %

11.04.	Enliven Therapeutics, Inc. gibt positive Proof-of-Concept-Daten aus der klinischen Phase-1-Studie mit ELVN-001 bei chronischer myeloischer Leukämie bekannt	CI
09.04.	Enliven Therapeutics, Inc. ernennt Lori Kunkel zum Mitglied des Verwaltungsrats	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	11.04.
Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	11.04.
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors	09.04.
Enliven Therapeutics, Inc. Appoints Lori Kunkel to Board of Directors	09.04.
Enliven Therapeutics, Inc. announced that it has received $90.000014 million in funding	03.04.
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024	28.03.
North American Morning Briefing : Investors -2-	21.03.
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates	19.03.
Enliven Therapeutics, Inc. announced that it expects to receive $90.000014 million in funding	19.03.
Enliven Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	14.03.
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14.03.
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference	27.02.
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to NASDAQ Biotechnology Index	18.12.
Enliven Therapeutics Q3 Loss Narrows	09.11.
Enliven Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update	09.11.
Enliven Therapeutics Insider Sold Shares Worth $104,999, According to a Recent SEC Filing	06.11.
Enliven Therapeutics Insider Sold Shares Worth $111,751, According to a Recent SEC Filing	06.11.
Enliven Therapeutics Insider Sold Shares Worth $163,498, According to a Recent SEC Filing	04.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Enliven Therapeutics, Inc.

Aktien

A3DGS0

US29337E1029

ELVN

Andere Sprachen

Filter